Cargando…

Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology

Emodin has shown pharmacological effects in the treatment of infection with severe acute respiratory syndrome coronavirus-2, which leads to coronavirus disease 2019 (COVID-19). Thus, we speculated that emodin may possess anti-COVID-19 activity. In this study, using bioinformatics databases, we scree...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Hai-Xia, Zhu, Jia-Qi, Chen, Jing, Zhou, Hui-Fen, Yang, Jie-Hong, Wan, Hai-Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221358/
https://www.ncbi.nlm.nih.gov/pubmed/34088885
http://dx.doi.org/10.18632/aging.203098
_version_ 1783711315595886592
author Du, Hai-Xia
Zhu, Jia-Qi
Chen, Jing
Zhou, Hui-Fen
Yang, Jie-Hong
Wan, Hai-Tong
author_facet Du, Hai-Xia
Zhu, Jia-Qi
Chen, Jing
Zhou, Hui-Fen
Yang, Jie-Hong
Wan, Hai-Tong
author_sort Du, Hai-Xia
collection PubMed
description Emodin has shown pharmacological effects in the treatment of infection with severe acute respiratory syndrome coronavirus-2, which leads to coronavirus disease 2019 (COVID-19). Thus, we speculated that emodin may possess anti-COVID-19 activity. In this study, using bioinformatics databases, we screened and harvested the candidate genes or targets of emodin and COVID-19 prior to the determination of pharmacological targets and molecular mechanisms of emodin against COVID-19. We discovered core targets for the treatment of COVID-19, including mitogen-activated protein kinase 1 (MAPK1), tumor protein (TP53), tumor necrosis factor (TNF), caspase-3 (CASP3), epidermal growth factor receptor (EGFR), vascular endothelial growth factor A (VEGFA), interleukin 1B (IL1B), mitogen-activated protein kinase 14 (MAPK14), prostaglandin-endoperoxide synthase 2 (PTGS2), B-cell lymphoma-2-like protein 1 (BCL2L1), interleukin-8 (CXCL8), myeloid cell leukemia-1 (MCL1), and colony stimulating factor 2 (CSF2). The GO analysis of emodin against COVID-19 mainly included cytokine-mediated signaling pathway, response to lipopolysaccharide, response to molecule of bacterial origin, developmental process involved in reproduction, and reproductive structure development. The KEGG results exhibited that the molecular pathways mainly included IL-17 signaling pathway, AGE-RAGE signaling pathway in diabetic complications, TNF signaling pathway, pertussis, proteoglycans in cancer, pathways in cancer, MAPK signaling pathway, NOD-like receptor signaling pathway, NF-kappa B signaling pathway, etc. Also, molecular docking results revealed the docking capability between emodin and COVID-19 and the potential pharmacological activity of emodin against COVID-19. Taken together, these findings uncovered the targets and pharmacological mechanisms of emodin for treating COVID-19 and suggested that the vital targets might be used as biomarkers against COVID-19.
format Online
Article
Text
id pubmed-8221358
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-82213582021-06-26 Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology Du, Hai-Xia Zhu, Jia-Qi Chen, Jing Zhou, Hui-Fen Yang, Jie-Hong Wan, Hai-Tong Aging (Albany NY) Research Paper Emodin has shown pharmacological effects in the treatment of infection with severe acute respiratory syndrome coronavirus-2, which leads to coronavirus disease 2019 (COVID-19). Thus, we speculated that emodin may possess anti-COVID-19 activity. In this study, using bioinformatics databases, we screened and harvested the candidate genes or targets of emodin and COVID-19 prior to the determination of pharmacological targets and molecular mechanisms of emodin against COVID-19. We discovered core targets for the treatment of COVID-19, including mitogen-activated protein kinase 1 (MAPK1), tumor protein (TP53), tumor necrosis factor (TNF), caspase-3 (CASP3), epidermal growth factor receptor (EGFR), vascular endothelial growth factor A (VEGFA), interleukin 1B (IL1B), mitogen-activated protein kinase 14 (MAPK14), prostaglandin-endoperoxide synthase 2 (PTGS2), B-cell lymphoma-2-like protein 1 (BCL2L1), interleukin-8 (CXCL8), myeloid cell leukemia-1 (MCL1), and colony stimulating factor 2 (CSF2). The GO analysis of emodin against COVID-19 mainly included cytokine-mediated signaling pathway, response to lipopolysaccharide, response to molecule of bacterial origin, developmental process involved in reproduction, and reproductive structure development. The KEGG results exhibited that the molecular pathways mainly included IL-17 signaling pathway, AGE-RAGE signaling pathway in diabetic complications, TNF signaling pathway, pertussis, proteoglycans in cancer, pathways in cancer, MAPK signaling pathway, NOD-like receptor signaling pathway, NF-kappa B signaling pathway, etc. Also, molecular docking results revealed the docking capability between emodin and COVID-19 and the potential pharmacological activity of emodin against COVID-19. Taken together, these findings uncovered the targets and pharmacological mechanisms of emodin for treating COVID-19 and suggested that the vital targets might be used as biomarkers against COVID-19. Impact Journals 2021-06-04 /pmc/articles/PMC8221358/ /pubmed/34088885 http://dx.doi.org/10.18632/aging.203098 Text en Copyright: © 2021 Du et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Du, Hai-Xia
Zhu, Jia-Qi
Chen, Jing
Zhou, Hui-Fen
Yang, Jie-Hong
Wan, Hai-Tong
Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology
title Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology
title_full Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology
title_fullStr Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology
title_full_unstemmed Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology
title_short Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology
title_sort revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221358/
https://www.ncbi.nlm.nih.gov/pubmed/34088885
http://dx.doi.org/10.18632/aging.203098
work_keys_str_mv AT duhaixia revealingthetherapeutictargetsandmolecularmechanismsofemodintreatedcoronavirusdisease2019viaasystematicstudyofnetworkpharmacology
AT zhujiaqi revealingthetherapeutictargetsandmolecularmechanismsofemodintreatedcoronavirusdisease2019viaasystematicstudyofnetworkpharmacology
AT chenjing revealingthetherapeutictargetsandmolecularmechanismsofemodintreatedcoronavirusdisease2019viaasystematicstudyofnetworkpharmacology
AT zhouhuifen revealingthetherapeutictargetsandmolecularmechanismsofemodintreatedcoronavirusdisease2019viaasystematicstudyofnetworkpharmacology
AT yangjiehong revealingthetherapeutictargetsandmolecularmechanismsofemodintreatedcoronavirusdisease2019viaasystematicstudyofnetworkpharmacology
AT wanhaitong revealingthetherapeutictargetsandmolecularmechanismsofemodintreatedcoronavirusdisease2019viaasystematicstudyofnetworkpharmacology